Knowles S, Gupta A K, Shear N H
Department of Medicine, Sunnybrook Health Science Centre and the University of Toronto, Ontario, Canada.
J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):201-6. doi: 10.1016/s0190-9622(98)70241-5.
Cutaneous reactions ranging from exanthems to severe adverse events have been reported in association with calcium channel blockers.
Our purpose was to document cutaneous eruptions resulting from use of diltiazem.
We describe three patients who experienced a cutaneous reaction (i.e., hypersensitivity syndrome reaction, pruritic exanthematous eruption, and acute generalized exanthematous pustulosis) possibly induced by diltiazem, summarize adverse reaction reports obtained from the Health Protection Branch, and review the literature on calcium channel blockers inducing cutaneous reactions.
Of the 315 cases of possible diltiazem-induced adverse reactions that were reported to the Health Protection Branch, 151 (48%) were cutaneous. The number of diltiazem-induced cutaneous events was significantly greater than those induced by either nifedipine or verapamil. However, no difference was found in the proportion of serious cutaneous adverse events to either of the three drugs.
Diltiazem has been associated with a variety of cutaneous reactions that appear to occur more frequently than with other calcium channel blockers.
已有报道称钙通道阻滞剂与从皮疹到严重不良事件的皮肤反应有关。
我们的目的是记录使用地尔硫䓬引起的皮肤疹。
我们描述了三名可能由地尔硫䓬引起皮肤反应（即过敏综合征反应、瘙痒性皮疹和急性泛发性脓疱病）的患者，总结了从健康保护局获得的不良反应报告，并回顾了关于钙通道阻滞剂引起皮肤反应的文献。
向健康保护局报告的315例可能由地尔硫䓬引起的不良反应中，151例（48%）为皮肤反应。地尔硫䓬引起的皮肤事件数量明显多于硝苯地平或维拉帕米引起的。然而，三种药物中任何一种的严重皮肤不良事件比例均无差异。
地尔硫䓬与多种皮肤反应有关，这些反应似乎比其他钙通道阻滞剂更频繁地发生。
